由于治疗或潜在疾病，免疫功能低下 (IC) 成年人患带状疱疹 (HZ) 和带状疱疹相关并发症的风险增加。本研究评估了美国 (US) 的造血干细胞移植 (HSCT) 受者和其他年龄 18 岁以上的 IC 成年人中，重组带状疱疹疫苗 (RZV) 与不接种疫苗预防带状疱疹的成本效益。静态马尔可夫模型使用 1 年周期长度和 30 年时间范围模拟 IC 个体队列来估计 RZV 的成本效益。输入数据来自临床试验结果和公开来源/文献。建模人群包括美国成人 HSCT 受者（基本案例）、人类免疫缺陷病毒 (HIV) 患者、乳腺癌患者、霍奇金淋巴瘤患者和肾移植受者。该模型报告了社会成本、质量调整生命年（QALY）和增量成本效益比（ICER）。进行了敏感性和阈值分析。在 19,671 名美国成人 HSCT 接受者的基本案例中，与不接种疫苗相比，RZV 节省了 10 万美元的总社会成本，并增加了 109 个 QALY。与不接种疫苗相比，RZV 是一种“主导策略”，因为疫苗接种可以节省成本并提高 QALY。 RZV 还可以节省肾移植受者的成本，并且在艾滋病毒、乳腺癌和霍奇金淋巴瘤患者中，每获得 QALY 的支付意愿门槛为 100,000 美元，具有成本效益，ICER 分别为 33,268 美元、67,682 美元和 67,682 美元。与不接种疫苗相比，每个 QALY 分别获得 95,972 美元。模型结果显示，RZV 对于美国成人 HSCT 接受者和患有特定免疫功能低下疾病的美国成年人预防带状疱疹可能节省成本，并且对于其他人来说具有成本效益，支持使用 RZV 来预防带状疱疹。 IC 成人带状疱疹和带状疱疹相关并发症。© 2023。GSK。

Immunocompromised (IC) adults are at increased risk of developing herpes zoster (HZ) and HZ-related complications due to therapy or underlying disease. This study evaluated the cost effectiveness of recombinant zoster vaccine (RZV) versus no vaccine for the prevention of HZ in hematopoietic stem cell transplant (HSCT) recipients and other IC adults aged ≥ 18 years in the United States (US).A static Markov model simulated cohorts of IC individuals using a 1-year cycle length and 30-year time horizon to estimate the cost effectiveness of RZV. Inputs were sourced from clinical trial results and publicly available sources/literature. Modeled populations included US adult HSCT recipients (base case), patients with human immunodeficiency virus (HIV), patients with breast cancer, patients with Hodgkin's lymphoma, and renal transplant recipients. The model reported societal costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Sensitivity and threshold analyses were conducted.In the base case of 19,671 US adult HSCT recipients, RZV resulted in total societal cost savings of US$0.1 million and 109 incremental QALYs versus no vaccine. RZV was a 'dominant strategy' versus no vaccine because vaccination resulted in cost savings with QALY gains. RZV was also cost saving in renal transplant recipients, and cost effective at a willingness-to-pay threshold of US$100,000 per QALY gained in patients with HIV, breast cancer, and Hodgkin's lymphoma, with ICERs of US$33,268, US$67,682, and US$95,972 per QALY gained, respectively, versus no vaccine.Model results show RZV is potentially cost saving for the prevention of HZ in US adult HSCT recipients and US adults with selected immunocompromising conditions, and cost effective for others, supporting the use of RZV to prevent HZ and HZ-related complications in IC adults.© 2023. GSK.